Matthew Ej Callister

List of Publications by Year
in descending order

52 papers	2,294 citations	331670 21 h-index	214800 47 g-index
54 all docs	54 docs citations	54 times ranked	3070 citing authors

#	Article	IF	Citations
1	Associations between general practice characteristics and chest x-ray rate: an observational study. British Journal of General Practice, 2022, 72, BJGP.2021.0232.	1.4	2
2	Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling. Health Technology Assessment, 2022, 26, 1-180.	2.8	0
3	Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom. British Journal of Cancer, 2021, 124, 2026-2034.	6.4	30
4	Chest X-ray sensitivity and lung cancer outcomes: a retrospective observational study. British Journal of General Practice, 2021, 71, e862-e868.	1.4	12
5	A prospective cohort evaluation of the sensitivity and specificity of the chest X-ray for the detection of lung cancer in symptomatic adults. European Journal of Radiology, 2021, 144, 109953.	2.6	3
6	Estimating lung cancer risk from chest X-ray and symptoms: a prospective cohort study. British Journal of General Practice, 2021, 71, e280-e286.	1.4	14
7	Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk. BMJ Open, 2020, 10, e037075.	1.9	48
8	Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme. BMJ Open, 2020, 10, e037086.	1.9	31
9	SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. European Respiratory Journal, 2020, 56, 2000118.	6.7	27
10	External validation of a convolutional neural network artificial intelligence tool to predict malignancy in pulmonary nodules. Thorax, 2020, 75, 306-312.	5.6	121
11	Sequential screening for lung cancer in a high-risk group: randomised controlled trial. European Respiratory Journal, 2019, 54, 1900581.	6.7	14
12	Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptoms: a systematic review. British Journal of General Practice, 2019, 69, e827-e835.	1.4	58
13	Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis. European Respiratory Journal, 2019, 53, 1801568.	6.7	18
14	Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol. Lancet Respiratory Medicine,the, 2019, 7, 655-656.	10.7	18
15	The proportion of lung cancer patients attending UK lung cancer clinics who would have been eligible for low-dose CT screening. European Respiratory Journal, 2019, 54, 1802221.	6.7	5
16	Level of accuracy of diagnoses recorded in discharge summaries: A cohort study in three respiratory wards. Journal of Evaluation in Clinical Practice, 2019, 25, 36-43.	1.8	21
17	Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients. Thorax, 2018, 73, 530-537.	5.6	35
18	The impact of three discharge coding methods on the accuracy of diagnostic coding and hospital reimbursement for inpatient medical care. International Journal of Medical Informatics, 2018, 115, 35-42.	3.3	17

#	Article	IF	Citations
19	British Thoracic Society quality standards for the investigation and management of pulmonary nodules. BMJ Open Respiratory Research, 2018, 5, e000273.	3.0	7
20	Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 502-508.	5.6	47
21	Minute ventilation-to-carbon dioxide slope is associated with postoperative survival after anatomical lung resection. Lung Cancer, 2018, 125, 218-222.	2.0	18
22	Lung cancer stage-shift following a symptom awareness campaign. Thorax, 2018, 73, 1128-1136.	5.6	72
23	EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC). Lung Cancer, 2018, 123, 149-154.	2.0	39
24	The Fleischner Society 2017 and British Thoracic Society 2015 guidelines for managing pulmonary nodules: keep calm and carry on. Thorax, 2018, 73, 806-812.	5.6	13
25	Secondary-care costs associated with lung cancer diagnosed at emergency hospitalisation in the United Kingdom. Thorax, 2017, 72, 950-952.	5.6	6
26	Poor preoperative patient-reported quality of life is associated with complications following pulmonary lobectomy for lung cancer. European Journal of Cardio-thoracic Surgery, 2017, 51, ezw363.	1.4	9
27	Defining the path: lung cancer CT screening in Europe. Thorax, 2017, 72, 778-779.	5.6	2
28	Physician Assessment of Pretest Probability of Malignancy and Adherence to Guidelines for Pulmonary Nodule Evaluation. Chest, 2017, 152, 447-448.	0.8	3
29	European position statement on lung cancer screening. Lancet Oncology, The, 2017, 18, e754-e766.	10.7	428
30	Patient reported outcomes following video assisted thoracoscopic (VATS) resection or stereotactic ablative body radiotherapy (SABR) for treatment of non-small cell lung cancer: protocol for an observational pilot study (LiLAC). Journal of Thoracic Disease, 2017, 9, 2703-2713.	1.4	8
31	Accuracy and cost-effectiveness of dynamic contrast-enhanced CT in the characterisation of solitary pulmonary nodules—the SPUtNIk study. BMJ Open Respiratory Research, 2016, 3, e000156.	3.0	6
32	Factors affecting hospital costs in lung cancer patients in the United Kingdom. Lung Cancer, 2016, 97, 8-14.	2.0	9
33	How should performance in EBUS mediastinal staging in lung cancer be measured?. British Journal of Cancer, 2016, 115, e9-e9.	6.4	15
34	Return of the pulmonary nodule: the radiologist's key role in implementing the 2015 BTS guidelines on the investigation and management of pulmonary nodules. British Journal of Radiology, 2016, 89, 20150776.	2.2	15
35	Pulmonary nodules again? The 2015 British Thoracic Society guidelines on the investigation and management of pulmonary nodules. Clinical Radiology, 2016, 71, 18-22.	1.1	12
36	How should pulmonary nodules be optimally investigated and managed?. Lung Cancer, 2016, 91, 48-55.	2.0	40

#	Article	IF	Citations
37	Modelling the cost-effectiveness of public awareness campaigns for the early detection of non-small-cell lung cancer. British Journal of Cancer, 2015, 113, 135-141.	6.4	12
38	The British Thoracic Society guidelines on the investigation and management of pulmonary nodules. Thorax, 2015, 70, 794-798.	5.6	393
39	Risk of malignancy in pulmonary nodules: A validation study of four prediction models. Lung Cancer, 2015, 89, 27-30.	2.0	135
40	Authors' response—Risk of malignancy in pulmonary nodules: a validation study of four prediction models. Lung Cancer, 2015, 90, 119-120.	2.0	1
41	Occult Nodal Disease in Patients With Non–Small-Cell Lung Cancer Who are Suitable for Stereotactic Ablative Body Radiation. Clinical Lung Cancer, 2014, 15, 466-469.	2.6	18
42	Clinical management of older people with non-small cell lung cancer in England. Thorax, 2012, 67, 836-839.	5.6	19
43	PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-κB-dependent proinflammatory activation of alveolar epithelial cells. British Journal of Pharmacology, 2008, 155, 661-672.	5.4	14
44	Ischaemic bowel within the thoracic cavity—An unusual cause of a pleural effusion. Respiratory Medicine CME, 2008, 1, 31-33.	0.1	1
45	Endobronchial ultrasound guided transbronchial needle aspiration of mediastinal lymph nodes for lung cancer staging: a projected cost analysis. Thorax, 2008, 63, 384-384.	5.6	32
46	Persistently low plasma thioredoxin is associated with meningococcal septic shock in children. Intensive Care Medicine, 2007, 33, 364-367.	8.2	10
47	Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax, 2006, 61, 521-527.	5.6	66
48	Thioredoxin: friend or foe in human disease?. Trends in Pharmacological Sciences, 2005, 26, 398-404.	8.7	192
49	KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. European Respiratory Journal, 2004, 23, 142-145.	6.7	93
50	Pulmonary tuberculosis among political asylum seekers screened at Heathrow Airport, London, 1995-9. Thorax, 2002, 57, 152-156.	5.6	49
51	Pulmonary versus extrapulmonary acute respiratory distress syndrome: different diseases or just a useful concept?. Current Opinion in Critical Care, 2002, 8, 21-25.	3.2	22
52	Descending Necrotizing Mediastinitis Caused by Group A Streptococcus (Serotype M1T1). Scandinavian Journal of Infectious Diseases, 2001, 33, 771-772.	1.5	9